XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS

8. GOODWILL AND INTANGIBLE ASSETS

Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2023 and 2022 was $17.9 million and $26.7 million, respectively. We have not recognized any impairment losses related to goodwill and intangible assets during the periods presented.

Intangible assets with definite lives are amortized over their estimated useful lives. The carrying basis and accumulated amortization of recognized intangible assets as of December 31, 2023 and 2022 were as follows:

 

 

 

December 31, 2023

 

 

 

Useful Life

 

Gross

 

 

Accumulated

 

 

Net Carrying

 

(In thousands)

 

(Years)

 

Amount

 

 

Amortization

 

 

Amount

 

Marketed products

 

8-10

 

$

219,700

 

 

$

(25,204

)

 

$

194,496

 

In-process research and development

 

 

 

 

2,600

 

 

 

 

 

 

2,600

 

Collaboration agreement

 

10

 

 

35,400

 

 

 

(2,161

)

 

 

33,239

 

Total

 

 

 

$

257,700

 

 

$

(27,365

)

 

$

230,335

 

 

 

 

December 31, 2022

 

 

 

Useful Life

 

Gross

 

 

Accumulated

 

 

Net Carrying

 

(In thousands)

 

(Years)

 

Amount

 

 

Amortization

 

 

Amount

 

Marketed products

 

8-10

 

$

151,000

 

 

$

(5,581

)

 

$

145,419

 

In-process research and development

 

 

 

 

72,100

 

 

 

 

 

 

72,100

 

Collaboration agreement

 

 

 

 

35,400

 

 

 

 

 

 

35,400

 

Total

 

 

 

$

258,500

 

 

$

(5,581

)

 

$

252,919

 

 

Intangible assets recognized as a result of the acquisition of Entasis amounted to $106.7 million, which consisted of Entasis’ in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $71.3 million and $35.4 million, respectively. Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. The useful life of the remaining in-process research and development of $2.6 million will be determined upon commercialization of the underlying product candidate; thus, no amortization expense for this intangible asset was recognized for the periods presented.

Intangible assets recognized as a result of the acquisition of La Jolla amounting to $151.0 million pertain to product rights and developed technologies on La Jolla’s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.

We recognized amortization expense of $21.8 million and $5.6 million for the years ended December 31, 2023 and 2022, respectively. Future amortization expense is expected to be $25.8 million for each of the years from 2024 to 2028 and $98.7 million thereafter.